Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21094294 | 0.89 | CCR9 (0.37) | KIF11SCN5ASCN9AESR1ESR2 | |
| SCHEMBL22477669 | 0.82 | FDPS (0.40) | ESR1ESR2TSHRALDH1A1HTT | |
| SCHEMBL22761971 | 0.81 | CCR9 (0.42) | KIF11SCN5ASCN9ACYP3A4TAAR1 | |
| SCHEMBL21740929 | 0.78 | ESR2 (0.39) | KIF11ESR1ESR2TAAR1 | |
| SCHEMBL22414493 | 0.77 | PNMT (0.38) | KIF11CYP3A4TAAR1PNMTPKM | |
| SCHEMBL19806049 | 0.76 | ESR1 (0.42) | KIF11ESR1ESR2TDP1CYP3A4 | |
| SCHEMBL25530522 | 0.76 | ESR1 (0.42) | ESR1TDP1CYP3A4TSHRMAPK1 | |
| SCHEMBL22649429 | 0.75 | GABRA1 (0.35) | ESR1ESR2NR3C1TDP1TSHR | |
| SCHEMBL24126779 | 0.74 | — | — | |
| SCHEMBL21302117 | 0.74 | ESR1 (0.40) | KIF11ESR1ESR2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | KIF11 4597/4885SCN5A 3519/4885SCN9A 456/4885 |
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | AHR, ARNT, AIPL1 | KIF11 4820/4885SCN5A 2817/4885SCN9A 3973/4885 |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | KIF11 2129/4885SCN5A 2501/4885SCN9A 4087/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | KIF11 4597/4885SCN5A 3519/4885SCN9A 456/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | KIF11 2129/4885SCN5A 2501/4885SCN9A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.